Physician profile
Atul Maini
NPI 1780876268
$2,272.67
in general payments reported to CMS, 2019-2025
20 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $14.42 · 2021: $173 · 2022: $271 · 2023: $630 · 2024: $259 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.39 |
| Education | $123.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $370.11 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $257.91 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $174.18 | 2025 | Lupkynis |
| Davol INC. | $169.00 | 2023-2025 | Phasix Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.37 | 2019-2025 | Jardiance |
| Amgen INC. | $152.70 | 2021-2023 | Tavneos |
| Boston Scientific Corporation | $132.21 | 2022 | |
| Opko Pharmaceuticals, LLC | $123.45 | 2024 | Rayaldee |
| Tela Bio, INC. | $120.37 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $116.13 | 2020-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $70.60 | 2019-2023 | Farxiga |
| Ucb, INC. | $70.23 | 2022-2023 | Briviact |
| Ardelyx, INC. | $66.26 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $65.04 | 2025 | Filspari |
| Horizon Therapeutics Plc | $62.52 | 2023 | Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $56.25 | 2025 | Renal - Pd |
| Ethicon US, LLC | $50.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $19.87 | 2023 | |
| Biogen, INC. | $17.07 | 2025 | Vumerity, Tysabri |
| Mallinckrodt Hospital Products INC. | $14.55 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Maini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.